Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.
The proteasome of Mycobacterium tuberculosis (Mtb) is a validated and drug-treatable target for therapeutics. To lay ground-work for developing peptide-based inhibitors with a useful degree of selectivity for the Mtb proteasome over those of the host, we used a library of 5,920 N-acetyl tripeptide-aminomethylcoumarins to contrast the substrate preferences of the recombinant Mtb proteasome wild type and open gate mutant, the Rhodococcus erythropolis proteasome, and the bovine proteasome with activator PA28. The Mtb proteasome was distinctive in strictly preferring P1 = tryptophan, particularly in combination with P3 = glycine, proline, lysine or arginine. Screening results were validated with Michalis-Menten kinetic analyses of 21 oligopeptide aminomethyl-coumarin substrates. Bortezomib, a proteasome inhibitor in clinical use, and 17 analogs varying only at P1 were used to examine the differential impact of inhibitors on human and Mtb proteasomes. The results with the inhibitor panel confirmed those with the substrate panel in demonstrating differential preferences of Mtb and mammalian proteasomes at the P1 amino acid. Changing P1 in bortezomib from Leu to m-CF(3)-Phe led to a 220-fold increase in IC(50) against the human proteasome, whereas changing a P1 Ala to m-F-Phe decreased the IC(50) 400-fold against the Mtb proteasome. The change of a P1 Ala to m-Cl-Phe led to an 8000-fold shift in inhibitory potency in favor of the Mtb proteasome, resulting in 8-fold selectivity. Combinations of preferred amino acids at different sites may thus improve the species selectivity of peptide-based inhibitors that target the Mtb proteasome.
Lin
Gang
G
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10065, USA. gal2005@med.cornell.edu
Tsu
Christopher
C
Dick
Lawrence
L
Zhou
Xi K
XK
Nathan
Carl
C
D000596:Amino Acids / Q000737:chemistry; D000818:Animals; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D002417:Cattle; D006801:Humans; D020128:Inhibitory Concentration 50; D007700:Kinetics; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000737:chemistry / Q000378:metabolism*; D009842:Oligopeptides / Q000737:chemistry; D010455:Peptides / Q000737:chemistry*; D046988:Proteasome Endopeptidase Complex / Q000737:chemistry; D011485:Protein Binding; D011719:Pyrazines / Q000494:pharmacology; D012240:Rhodococcus / Q000378:metabolism; D013379:Substrate Specificity
D000596:Amino Acids; D001897:Boronic Acids; D009842:Oligopeptides; D010455:Peptides; D011719:Pyrazines; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex